News & Updates
Filter by Specialty:
Survival benefit with STRIDE for HCC sustained at 5 years
The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).
Survival benefit with STRIDE for HCC sustained at 5 years
10 Jan 2025
Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC
First-line treatment with osimertinib plus platinum-pemetrexed chemotherapy (CTx) induces significant improvements in progression-free survival (PFS) among Asian patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), which is similar with the results seen in the global population of the FLAURA2 study.
Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC
08 Jan 2025
Retifanlimab plus chemo improves survival in metastatic NSCLC
The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.